[olsen]

Am J Clin Nutr. 2013 May;97(5):1004-13. doi: 10.3945/ajcn.112.051664. Epub 2013 Mar 13.
Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease.
Suzuki M, Yoshioka M, Hashimoto M, et al
BACKGROUND:
In our previous study, higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and the vitamin D receptor (VDR) FokI CC genotype were associated with milder Parkinson disease (PD).

OBJECTIVE:
We evaluated whether vitamin D3 supplementation inhibits the progression of PD on the basis of patient VDR subgroups.

DESIGN:
Patients with PD (n = 114) were randomly assigned to receive vitamin D3 supplements (n = 56; 1200 IU/d) or a placebo (n = 58) for 12 mo in a double-blind setting. Outcomes were clinical changes from baseline and the percentage of patients who showed no worsening of the modified Hoehn and Yahr (HY) stage and Unified Parkinson's Disease Rating Scale (UPDRS).



CONCLUSION:
Vitamin D3 supplementation may stabilize PD for a short period in patients with FokI TT or CT genotypes without triggering hypercalcemia, although this effect may be nonspecific for PD. This trial was registered at UMIN Clinical Trials Registry as UMIN000001841.

Comment in
Low vitamin D concentration exacerbates adult brain dysfunction. [Am J Clin Nutr. 2013]

http://www.vitamindwiki.com/Parkinso...3+RCT+May+2013